Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial

J. Raal, Frederick; Fourie, Nyda; Scott, Russell; Blom, Dirk; De Vries Basson, Matthys; Kayıkçıoğlu, Meral; Caldwell, Kate; Kallend, David; A. Stein, Evan; Investigators, LIBerate-HeFH; Turner, Traci; Bergeron, Jean; Çaku, Artuela; Elis, Avishay; Durst, Ronen; Yalım, Zafer; Kayıkçıoğlu, Meral; Kırılmaz, Bahadır; Çelik, Ataç; Duzen, Irfan; Oguzhan, Abdurraham; Başarıcı, İbrahim; J. Raal, Frederick; Blom, Dirk; Abelson, M; M de V Basson, Matthys; Burgess, Lesley; Fourie, Nyda; Heggen, Eli; Andreas Asprusten, Emil; Mehta, Vimal; Puri, Raman; Mehta, Ashwani; Gupta, Preeti; Chag, Milan; Pradhan, Akshyaya; Fuentes Jimenez, Francisco; Civeira Murillo, Fernando; Pinto Sala, Xavier; Scott, Russell

doi:10.1093/eurheartj/ehad596

Public

Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial

Published in European Heart Journal • Aug 28, 2023

Authors:

Frederick J. Raal

Nyda Fourie

Russell Scott

Abstract

BACKGROUND AND AIMS: Lerodalcibep, a novel small recombinant fusion protein of a proprotein convertase subtilisin/kexin type 9 gene-binding domain (adnectin) and human serum albumin, demonstrated highly effective low-density lipoprotein cholesterol (LDL-C) reduction with monthly 300 mg in 1.2 mL sub...

Subject

Medicine

Placebo

Confidence interval

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!